2020


Voluntary Announcement -APG-115 Granted Approval for the Phase Ib/II Clinical Study in China”

Download (pdf,68 KB)


Voluntary Announcement -Olverembatinib (HQP1351) of Ascentage Pharma is Included in the List of “Priority Review”

Download (pdf,69 KB)


Voluntary Announcement -APG-115 and APG-1252 Granted Orphan Drug Designation by the US FDA

Download (pdf,434 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2020

Download (pdf,538 KB)


Grant of Awards under the RSU Scheme

Download (pdf,435 KB)


Voluntary Announcement -APG-115 Granted Orphan Drug Designation by the FDA for the Treatment of Gastric Cancer

Download (pdf,436 KB)


2020 Interim Report

Download (pdf,1 MB)


Voluntary Announcement -APG-2575 Granted Second Orphan Drug Designation by the US FDA

Download (pdf,436 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2020

Download (pdf,642 KB)


Announcement of Unaudited Interim Results for the Six Months Ended June 30,2020

Download (pdf,266 KB)


Voluntary Announcement -Becoming A Constituent of the Hang Seng Family of Indexes

Download (pdf,65 KB)


Notice of Board Meeting

Download (pdf,61 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2020

Download (pdf,601 KB)


Voluntary Announcement – APG-115 Completed Dosing of the First Patient in Phase Ib Clinical Study in China

Download (pdf,63 KB)


Voluntary Announcement – APG-2575 Granted Orphan Drug Designation by the US FDA

Download (pdf,70 KB)


Next Day Disclosure Return

Download (pdf,253 KB)


Closing of Placing of New Shares under General Mandate

Download (pdf,476 KB)


2019 Environmental, Social and Governance Report

Download (pdf,3 MB)


Placing of New Shares under General Mandate

Download (pdf,167 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2020

Download (pdf,601 KB)


Voluntary Announcement – Clinical Collaboration with MSD

Download (pdf,69 KB)


Voluntary Announcement – Clinical Collaboration with Acerta Pharma, the Hematology Research and Development Center of Excellence of AstraZeneca

Download (pdf,70 KB)


Poll Results of the Annual General Meeting Held on June 19, 2020

Download (pdf,83 KB)


Voluntary Announcement – Submission of New Drug Application for HQP1351 in China

Download (pdf,69 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2020

Download (pdf,602 KB)


Voluntary Announcement – Latest Clinical Data of Apoptosis Targeting Drug Candidates was Presented at 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

Download (pdf,445 KB)


Voluntary Announcement – HQP1351 Granted Fast Track Designation by the US FDA

Download (pdf,70.5 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2020

Download (pdf,634 KB)


Voluntary Announcement – HQP1351 Granted Orphan Drug Designation by the U.S. FDA

Download (pdf,451KB)


Form of Proxy for the Annual General Meeting to Be Held on June 19, 2020

Download (pdf,218KB)


Notice of Annual General Meeting

Download (pdf,93KB)


2019 Annual Report

Download (pdf,1.78MB)


Proposed Re-election of Retiring Directors and Proposed Granting of General Mandates to Issue Shares and Repurchase Shares and Notice of Annual General Meeting

Download (pdf,235KB)


Voluntary Announcement – Approval for the Phase Ib/II Clinical Study of APG-2575 in China

Download (pdf,86 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2020

Download (pdf,459 KB)


Announcement of Annual Results for the Year Ended December 31, 2019

Download (pdf,315 KB)


Voluntary Announcement – APG-2575 completed dosing of first patient in Phase Ib/II trial in the U.S.

Download (pdf,467 KB)


Notice of Board Meeting

Download (pdf,127 KB)


Voluntary Announcement – Approvals obtained in China and U.S. for three phase Ib/II clinical trials of APG-2575

Download (pdf,468 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2020

Download (pdf,627 KB)


Voluntary Announcement – Approval of phase Ib/II clinical trial of APG-1387 for the treatment of advanced pancreatic cancer in combination with chemotherapy in China

Download (pdf,111 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2020

Download (pdf,343 KB)


Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2019


 

 

Voluntary Announcenment – Studies of HQP1351 nominated the “Best of ASH” at the 2019 American Society of Hematology Annual Meeting

Download (pdf,128 KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2019

Download (pdf,441 KB)

Next Day Disclosure Return

Download (pdf,259 KB)

FULL EXERCISE OF THE OVER-ALLOTMENT OPTION,STABILISING ACTIONS AND END OF STABILISATION PERIOD

Download (pdf,138 KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2019

Download (pdf,1015 KB)

Amended and Restated Memorandum and Articles of Association

Download (pdf,418 KB)

Terms of Reference for Nomination Committee

Download (pdf,145 KB)

Terms of Reference for Audit Committee

Download (pdf,143 KB)

Terms of Reference for Remuneration Committee

Download (pdf,148 KB)

List of Directors and their Roles and Functions

Download (pdf,123 KB)

Procedures for election as director

Download (pdf,122 KB)

Board Diversity policy

Download (pdf,121 KB)

Shareholders Communication Policy

Download (pdf,129 KB)

Global Offering – Allotment Results

Download (pdf,1505 KB)